JILIN AODONG(SZ:000623)2023-07-24 12:11Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. has 308 drug production approval numbers and 605 products listed in the medical insurance directory, including 199 products in the 2022 national version [2] - The company achieved a sales revenue of 2.868 billion yuan in 2022, a year-on-year increase of 24.50% [3] - The main business segments include pharmaceuticals, finance, and health, with traditional Chinese medicine (TCM) accounting for 59.01% of revenue [3] Group 2: Product Performance - The core product "Anshen Bnona Liquid" has annual sales exceeding 600 million yuan and has maintained steady growth over 40 years [4] - In 2022, the company had over 30 products with annual sales exceeding 1 million yuan, contributing to the rapid growth of the health sector [6] - The company’s health products include 11 items with annual sales over 10 million yuan [6] Group 3: Financial Performance - In Q1 2023, the company achieved a revenue of 788 million yuan, a year-on-year increase of 23.46%, and a net profit of 486 million yuan, up 719.23% [3] - The expected net profit for the first half of 2023 is between 989.29 million and 1.088 billion yuan, representing a growth of 100% to 120% compared to the previous year [3] Group 4: Investment and Shareholding - The company holds 19.72% of Guangfa Securities, with a market value of approximately 22.485 billion yuan [5] - The company has consistently increased its stake in Guangfa Securities since its initial investment in 1999, with no reductions in holdings [5] Group 5: Future Plans and Projects - The company plans to invest in several projects, including the TCM formula granule project, with an expected total investment of 1.002 billion yuan and projected annual sales of 1.263 billion yuan [7] - The company aims to enhance its marketing channels and expand its health product sales through various models, including digital e-commerce and live streaming [6]